Retatrutide · Access guidance
Explore trial eligibility or a physician-led access request with a starting estimate of $120 per month and care coordination included. Your plan and any medication supply are confirmed individually.
/ month
Starting planning estimate · Care coordination included
Your plan and any medication supply are confirmed individually. Additional services are quoted before you decide.Investigational; not FDA-approved. Eligibility and external approvals apply. SYNERGY-Outcomes is for higher-risk fatty liver disease and may assign retatrutide, tirzepatide, or placebo.
Two routes to discuss
We help clarify which next step may be appropriate. The responsible study team or treating physician confirms your eligibility.
Lilly-sponsored study · NCT07165028
For adults with higher-risk metabolic dysfunction-associated steatotic liver disease (MASLD). Lilly’s U.S. questionnaire can connect a potential match with a study nurse.
See Lilly’s study external siteIndividual assessment · NCT07629401
A potential route for select adults with severe obesity and serious complications who cannot join a suitable trial. Your treating physician submits the request; sponsor and regulatory approvals are required.
Discuss with our Care teamClinical records, testing, and paperwork stay in the medical care process. Your SEINE BIO account can show a simple progress update.
Create a free account and tell the Care team you want to explore Retatrutide access.
Your clinician reviews the relevant criteria and arranges additional records or appropriate testing when needed.
For SYNERGY, use Lilly’s questionnaire. For expanded access, the treating physician handles the request and required approvals.
See a concise status in your account when staff publishes an update. The responsible external team makes the final access decision.
Research background
Four findings from an 80-week trial in adults with obesity without diabetes. Knee-pain and sleep-apnea findings apply to the participants with those conditions. TRIUMPH-1 is closed to new enrollment.
Lilly reported this result at 80 weeks in the 12 mg group, compared with 2.2% for placebo, using the efficacy estimand. The treatment-regimen estimate was 25.0% versus 3.9%. These are study averages, not a personal forecast.
Read the study results external siteWaist circumference · 12 mg
In Lilly’s efficacy analysis, waist circumference fell an average of 24.1 cm (9.5 inches) at 80 weeks, compared with 3.6 cm (1.4 inches) with placebo.
Read the study results external siteKnee osteoarthritis subgroup · 12 mg
In the 574-participant knee-osteoarthritis substudy, pain scores improved by 4.1 points with 12 mg versus 2.5 points with placebo at 80 weeks, in the published intention-to-treat analysis.
Explore the published findings external siteSleep apnea subgroup · 12 mg
In the 243-participant sleep-apnea substudy, breathing-event rates fell by 32.1 per hour with 12 mg versus 9.6 with placebo at 80 weeks, in the published intention-to-treat analysis.
Explore the published findings external siteResults are study averages, not personal forecasts. Common adverse effects were gastrointestinal. Retatrutide remains investigational; review the full research and individual risks with a clinician.
Good questions
The planning estimate starts at $120 per month with care coordination included. Your exact plan, services and any medication supply are confirmed individually. Additional services are quoted before you decide. This estimate does not establish a clinical-trial fee or guarantee medication or enrollment.
Payment is made upfront after your plan and price are confirmed. If your request is not approved, we refund your payment. If you choose an alternative, we explain its price and confirm any payment adjustment with you first. This policy is separate from study enrollment and does not promise trial acceptance or medication.
No. It studies adults with high-risk MASLD, a fatty liver condition, using specific liver testing and other criteria. The study team confirms the complete requirements and current availability.
Open Lilly’s SYNERGY-Outcomes page and choose “See if You May Qualify.” If you appear to be a preliminary fit, a study nurse can discuss the next steps. You can also call the study nurse at 1-844-200-7254. SEINE BIO is not presented as a Lilly affiliate or study site.
No. SYNERGY-Outcomes randomly assigns participants to retatrutide, tirzepatide, or placebo. Screening and study consent explain the assignment process.
Ask your treating physician whether expanded access merits consideration. The listed program has strict criteria, including severe refractory obesity, serious complications, and inability to join a suitable trial. It also requires sponsor and regulatory approvals; it is not an automatic alternative.
No. A free account is available and paid membership is optional. Care coordination is included at no extra charge. Additional services are quoted individually before you decide. SEINE BIO does not sell Retatrutide through this pathway, and purchases do not affect study eligibility.
It records the external decision for the named request. It does not create a prescription, guarantee study assignment, or authorize a retail purchase. Your care team explains any remaining steps.
Common reported adverse events included nausea, diarrhea, constipation, and vomiting. In the 12 mg group, 11.3% discontinued because of adverse events, versus 4.9% for placebo. Review the full research and individual risks with a clinician.
Keep exploring
